Efficiency of nilotinib to target chronic phase-chronic myeloid leukaemia primary mature CD34^- and immature CD34⁺ cells.

Conversely, the relationship with the therapeutic response at month 3, 6 and 12 was almost significant, possibly due to lack of statistical power explained by the high number of patients in whom CD34 + cells did not accumulate nilotinib.

also in 1,858 other papers